Cargando…
Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to...
Autores principales: | Miesbach, Wolfgang, Menne, Jan, Bommer, Martin, Schönermarck, Ulf, Feldkamp, Thorsten, Nitschke, Martin, Westhoff, Timm H., Seibert, Felix S., Woitas, Rainer, Sousa, Rui, Wolf, Michael, Walzer, Stefan, Schwander, Björn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858672/ https://www.ncbi.nlm.nih.gov/pubmed/31730475 http://dx.doi.org/10.1186/s13023-019-1240-0 |
Ejemplares similares
-
Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020) -
Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018) -
Caplacizumab in adult patients with acquired thrombotic
thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020) -
Tozinameran: Acquired thrombotic thrombocytopenic purpura: case report
Publicado: (2022) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)